Journals / İstanbul Kuzey Klinikleri / 2019 / Cilt: 6 - Sayı: 1

Is high level of hemoglobin A1C an indicator for extended period of antibiotherapy in diabetic foot ulcers?

Pages
21–27
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The “7–15%” subgroups of HbA1Clevel patients showed statistically significant prolongation of the antibiotherapy time (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Diabetic foot ulcers are the most common cause of hospitalization among the diabetic complications.
📊
Key Findings & Data:Hemoglobin A1C (HbA1C) has a critical role in medical follow-up of diabetic patients.
💡
Conclusion & Impact:The “7–15%” subgroups of HbA1Clevel patients showed statistically significant prolongation of the antibiotherapy time (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Diabetic foot ulcers are the most common cause of hospitalization among the diabetic complications. Hemoglobin A1C (HbA1C) has a critical role in medical follow-up of diabetic patients. In fact, the role of HbA1C and related clinical parameters has been investigated in literature there are only a few studies investigating the relationship between HbA1Cand the prolonged antibiotherapy. We aim to reveal the reciprocal relationship between this two parameters.METHODS: The clinical data of 139 patients who admitted with diabetic foot ulcers are analyzed retrospectively. Besides thedemographic information, the levels of HbA1C wound localizations, the degree of the wounds regarding the Wagner classification, culture antibiogram, and the duration of the antibiotic agents. The data have been analyzed with IBM SPSS Statistics(IBM Statistical Package for the Social Sciences) for Windows 22.0.RESULTS: The clinical data of the 139 diabetic foot patients are retrospectively assessed. The mean age was 56.50 (±4.12).There were 81 male (58.27%) and 58 (41.73%) female patients. The distal type diabetic foot ulcers were found to be themost frequent type (n=83, 59.71% [±3.12]). The mean HbA1C level was 9.60 (±1.10). The “7–15%” subgroups of HbA1Clevel patients showed statistically significant prolongation of the antibiotherapy time (p

🔖

Cite This Article

ONAR, L. Ç., DOGAN, M., GÜMÜŞTAŞ, S. A., AYDIN, B. (2022). Is high level of hemoglobin A1C an indicator for extended period of antibiotherapy in diabetic foot ulcers?. İstanbul Kuzey Klinikleri, Cilt: 6 - Sayı: 1, 21–27. https://ajindex.com/articles/551461

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, et al. 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. IDSA Guideline CID 2012:54
  2. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003;361:1545–51. [CrossRef ] 3. Monteiro-Soares M, Ribas R, Pereira da Silva C, Bral T, Mota A, Pinheiro Torres S, et al. Diabetic foot ulcer development risk classifications’ validation: A multicentre prospective cohort study. Diabetes Res Clin Pract 2017;127:105–14. [CrossRef ] 4. Laing P. The development and complications of diabetic foot ulcers. Am J Surg 1998;176:11S–9S. [CrossRef ] 5. Bennett PJ, Stocks AE, Whittam DJ. Analysis of risk factors for neuropathic foot ulceration in diabetes mellitus. J Am Podiatr Med Assoc 1996;86:112–6. [CrossRef ] 6. Ertugrul BM, Lipsky BA, Guvenc U; Turkish Intralesional Epidermal Growth Factor Study Group for Diabetic Foot Wounds. An assessment of intralesional epidermal growth factor for treating diabetic foot wounds the first experiences in Turkey. J Am Podiatr Med Assoc 2017;107:17–29. [CrossRef ] 7. Lepore G, Maglio ML, Cuni C, Dodesini AR, Nosari I, Minetti B, et al. Poor glucose control in the year before admission as a powerful predictor of amputation in hospitalized patients with diabetic foot ulceration. Diabetes Care 2006;29:1985. [CrossRef ] 8. Slovenkai MP. Foot problems in diabetes. Med Clin North Am 1998;82:949–71. [CrossRef ] 9. Bresäter LE, Welin L, Romanus B. Foot pathology and risk factors for diabetic foot disease in elderly men. Diabetes Res Clin Pract 1996;32:103–9. [CrossRef ] 10. Baktıroğlu S. Cerrahi infeksiyon. In: Sayek İ, editor. Diyabet ve infek siyon. Ankara: Güneş Kitabevi; 2000. p. 64–73
  3. Bridges RM Jr, Deitch EA. Diabetic foot infections. Pathophysiology and treatment. Surg Clin North Am 1994;74:537–55. [CrossRef ] 12. Eren Z. Davutoğlu M, Ulay M, Özsoy Z, Olcay E. Bayca 1. Diabetik ayak infeksiyonları. Türk Diyabet Yıllığı 1998-99;323–7
  4. Ünlühızarcı K, Doğanay M, Keleştimur F. Diabetic Foot Infections. Turkish Annual of Diabetes 1995:98–102
  5. New JP, McDowell D, Burns E, Young RJ. Problem of amputations in patients with newly diagnosed diabetes mellitus. Diabet Med 1998;15:760–4. [CrossRef ] 15. Akalın EH, Hayran M, Özdemir O, Açbay Ö, Aydın N, Ayvaz G, et al. Direct Medical Cost Analysis in Patients with Diabetes Mellitus in Turkey: Diabcost. Turk J Endocrinol Metab 1998:9–14. 16.